Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age
This article discusses nirsevimab, its side effects, and its implications for the nursing field. Respiratory syncytial virus (RSV) is a common virus infecting infants, causing …
Ask aRCie
Nirsevimab: A Review
This review article focuses on nirsevimab, a new monoclonal antibody approved by the FDA in July 2023 to prevent RSV disease in infants and young …
CDC Changes Recommendations Due to Severe Nirsevimab Shortage During the 2023-2024 RSV Season
2024
· Dow University of Health Sciences,
· D.G Khan Medical College,
· Kabul University of Medical and Sciences
This article describes how the CDC changed its recommendations because of a severe shortage of nirsevimab during the 2023-2024 RSV season. Nirsevimab is important for …
Cost-Effectiveness of Nirsevimab and Palivizumab for Respiratory Syncytial Virus Prophylaxis in Preterm Infants 29-34 6/7 Weeks' Gestation in the United States
This study compares the cost-effectiveness of two drugs, nirsevimab and palivizumab, used to prevent respiratory syncytial virus (RSV) in preterm infants born between 29 and …
Understanding New Recommendations for Respiratory Syncytial Virus Prevention in Pregnancy
2024
· Duke University
This article explains new guidelines for preventing respiratory syncytial virus (RSV) in pregnant women. RSV is a major cause of illness in infants. Previously, prevention …
Nirsevimab for Prevention of RSV Hospitalizations in Infants
2024
· The University of Kansas
This article comments on the HARMONIE trial, which concluded that nirsevimab reduced hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract infection in infants. The …
Recent Advances in the Prevention of Respiratory Syncytial Virus in Pediatrics
This review article highlights new developments in respiratory syncytial virus (RSV) prevention in pediatric patients and safety considerations for clinical trials. It describes two new …
Disparities in the Availability and Acceptance of Nirsevimab in Massachusetts
This research brief examines the differences in how nirsevimab, a treatment for RSV in infants, is available and accepted across Massachusetts. It describes that larger …
Society for Maternal-Fetal Medicine Statement: Clinical Considerations for the Prevention of Respiratory Syncytial Virus Disease in Infants
This statement from the Society for Maternal-Fetal Medicine focuses on preventing respiratory syncytial virus (RSV) in infants. It describes two main prevention methods: a vaccine …
Nirsevimab and Hospitalization for RSV Bronchiolitis
2024
· Paris Cité University,
· Sorbonne University,
· INSERM Unité
This study looks at how well nirsevimab, a monoclonal antibody, works in preventing hospitalizations for RSV bronchiolitis in infants under 12 months. Conducted across multiple …